Science & Research

Nanotechnology Task Force

About the Task Force

The FDA Nanotechnology Task Force (Task Force), formed in August 2006, is charged with determining regulatory approaches that encourage the continued development of innovative, safe, and effective FDA-regulated products that use nanotechnology materials. The Task Force continues to  identify and recommend ways to address any knowledge or policy gaps that exist to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials. 

The Task Force reports to the Chief Scientist, within the Office of the Commissioner.  Task Force members are designated representatives from all FDA Centers and Offices.

Nanotechnology Task Force Report

Page Last Updated: 03/23/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English